Biomarkers for prognosis, safety and response to oral immunotherapy treatment in allergy to cow’s milk proteins.
In developed countries, the frequency of allergy to cow's milk proteins is 2-3% of total population. In our country, 1-2 children per hundred develop allergy to cow's milk proteins within the first year of life. This is usually transient, and the average age of tolerance is four years (66% tolerance). After six years is more difficult to achieve tolerance and milk allergy often remains until adulthood, and therefore from that age can be considered persistent allergy. Just in Madrid born 70,000 children a year, about 1,700 will be allergic and 510 will be allergic persistent.
Currently there is not an active treatment for milk allergy. One option for persistent allergic children is oral immunotherapy (OIT), which consists on daily administration of small doses of milk, below the response threshold of the individual, successively increased to achieve tolerance to regular intakes. Thus, diminished the risk of patients’ reactions to the inadvertent ingestion of dairies, and is accomplished in some cases with complete tolerance. This treatment has been proven effective in 70-90% of children with milk allergy.
The present invention relates to a method for the prognosis and monitoring (duration of treatment, the risk of allergic reactions) treatment of allergy cow's milk proteins in OIT by determining IgE or IgG4 antibodies with the peptide sequences identified by the research group in an isolated sample from a subject.
Protected by Spanish patent application P201331200 with priority date of 08/01/2013, PCT/ES2014/070634 del 08/01/2014, national phases in Brazil, Chile, USA, México, Japan, EPO, Australia, Colombia, Canada.
Diego Velasco, Innovation Head
Emma González, Innovation Manager, PhD
Phone numbers: +34 91336 9132 / 9133
- Comercializado, Transferible
- Health technology:
- Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)